<?xml version='1.0' encoding='utf-8'?>
<document id="24732905"><sentence text="Colchicine-Induced Myopathy in a Tacrolimus-Treated Renal Transplant Recipient: Case Report and Literature Review." /><sentence text="Renal transplant recipients are prone to develop drug toxicities because of polypharmacy and drug-drug interactions" /><sentence text=" Colchicine is often used for the treatment of gout in these patients as nonsteroidal medications are contraindicated"><entity charOffset="1-11" id="DDI-PubMed.24732905.s3.e0" text="Colchicine" /></sentence><sentence text=" In addition, patients are often on corticosteroids and frequent, periodic, dose escalation for gouty flare may lead to side effects"><entity charOffset="36-51" id="DDI-PubMed.24732905.s4.e0" text="corticosteroids" /></sentence><sentence text=" Colchicine-induced myopathy has been very well described in the literature"><entity charOffset="1-11" id="DDI-PubMed.24732905.s5.e0" text="Colchicine" /></sentence><sentence text=" Several cases of colchicine toxicity have been reported in cyclosporine-treated patients due to a drug-drug interaction"><entity charOffset="18-28" id="DDI-PubMed.24732905.s6.e0" text="colchicine" /><entity charOffset="60-72" id="DDI-PubMed.24732905.s6.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.24732905.s6.e0" e2="DDI-PubMed.24732905.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24732905.s6.e0" e2="DDI-PubMed.24732905.s6.e1" /></sentence><sentence text=" We report a 62-year-old African American renal transplant recipient who had been doing well on tacrolimus-based immunosuppression and was started on colchicine (0"><entity charOffset="96-106" id="DDI-PubMed.24732905.s7.e0" text="tacrolimus" /><entity charOffset="150-160" id="DDI-PubMed.24732905.s7.e1" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.24732905.s7.e0" e2="DDI-PubMed.24732905.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24732905.s7.e0" e2="DDI-PubMed.24732905.s7.e1" /></sentence><sentence text="6 mg twice daily) for gouty flare" /><sentence text=" A few days later, he was found to have a 4-fold increase in aspartate aminotransferase and an elevated creatine phosphokinase"><entity charOffset="61-70" id="DDI-PubMed.24732905.s9.e0" text="aspartate" /></sentence><sentence text=" Although this interaction is very well known with cyclosporine, it has not yet been reported in patients on tacrolimus"><entity charOffset="51-63" id="DDI-PubMed.24732905.s10.e0" text="cyclosporine" /><entity charOffset="109-119" id="DDI-PubMed.24732905.s10.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.24732905.s10.e0" e2="DDI-PubMed.24732905.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24732905.s10.e0" e2="DDI-PubMed.24732905.s10.e1" /></sentence><sentence text=" " /></document>